<SEC-DOCUMENT>0001193125-18-205702.txt : 20180627
<SEC-HEADER>0001193125-18-205702.hdr.sgml : 20180627
<ACCEPTANCE-DATETIME>20180627160713
ACCESSION NUMBER:		0001193125-18-205702
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180627
DATE AS OF CHANGE:		20180627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219172
		FILM NUMBER:		18921878

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d631920d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5) <BR>Registration Statement No. 333-219172 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per Share</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common&nbsp;Stock,&nbsp;$0.01&nbsp;par&nbsp;value&nbsp;per&nbsp;share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">5,822,785</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$30.75</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$179,050,638.75</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$22,291.80</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated in accordance with Rule&nbsp;457(c) solely for purposes of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based on the average of the high and low
sale price of the registrant&#146;s common stock as reported on The NASDAQ Capital Market on June&nbsp;20, 2018. </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS&nbsp;SUPPLEMENT
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated July&nbsp;6, 2017) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,063,292 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g631920g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering
5,063,292&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market under the symbol &#147;HRTX.&#148; On
June&nbsp;22, 2018, the last reported sale price of our common stock was $41.35 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves
certain risks. See &#147;<A HREF="#supptoc631920_18">Risk Factors</A>&#148; beginning on Page&nbsp;S-12 of this prospectus supplement and in the accompanying prospectus, and in the other documents that are incorporated by reference and any related
free writing prospectus, for certain risks you should consider. You should read the entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference, carefully before you make your investment
decision. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has agreed to purchase 5,063,292&nbsp;shares of our common stock from us at a price of $38.445 per share,
which will result in approximately $194.7&nbsp;million of net proceeds to us, before deducting estimated offering expenses payable by us. The underwriter may offer the shares of common stock from time to time to purchasers directly or through
agents, or through brokers in brokerage transactions on The Nasdaq Capital Market, or to dealers in negotiated transactions, or in a combination of such methods of sale or otherwise, at a fixed price or prices, which may be changed, or at market
prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. See &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter may also exercise its option to purchase up to an additional 759,493&nbsp;shares of common stock from us, at a price of
$38.445 per share, for 30 days after the date of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission nor
any other regulatory body has approved or disapproved of these securities or passed on the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares will be ready for delivery on or about June&nbsp;28, 2018. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Book-Running Manager </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
Supplement dated June&nbsp;25, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_14">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_15">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_16">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_17">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_18">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_19">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_23">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc631920_24">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_7">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_12">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus supplement and the accompanying
prospectus, including any information incorporated by reference, and in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriter has not, authorized anyone to provide you with
different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should not assume that the information contained in this prospectus supplement and the accompanying prospectus, or in any free
writing prospectus that we have authorized for use in connection with this offering, is accurate as of any date other that the date of those respective documents, or that information contained in any document incorporated by reference is accurate as
of any date other than the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriter is not, making offers to sell these
securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or
solicitation. You should read this prospectus supplement, the accompanying prospectus, including any information incorporated by reference, and any free writing prospectus that we have authorized for use in connection with this offering in their
entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#147;Information Incorporated by Reference&#148; and &#147;Where You Can Find
Additional Information.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_14"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus form part of a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> that we filed with the U.S.&nbsp;Securities and Exchange Commission (the &#147;SEC&#148;) using a shelf registration process. This document contains two parts. The first part consists of this
prospectus supplement, which provides you with specific information about this offering. The second part consists of the accompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when
we refer only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this
prospectus supplement is inconsistent with statements made in the accompanying prospectus, or any documents incorporated by reference, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the
accompanying prospectus, including the documents incorporated by reference therein. Information in any document we subsequently file that is incorporated by reference shall modify or supersede the information in the prospectus supplement, the
accompanying prospectus and documents incorporated by reference prior to such subsequent filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus supplement,
&#147;Heron,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; and similar terms refer to Heron Therapeutics, Inc. References to our &#147;common stock&#148; refer to the common stock of Heron Therapeutics, Inc.
Heron Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the Heron logo, SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, CINVANTI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Biochronomer<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks. All other trademarks appearing or incorporated by reference into this prospectus supplement are the property of their respective owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this prospectus supplement to our financial statements include, unless the context indicates otherwise, the related notes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The industry and market data and other statistical information contained in this prospectus supplement, the accompanying prospectus and
the documents we incorporate by reference are based on management&#146;s own estimates, independent publications and reports by market research firms or other published independent sources and, in each case, are believed by management to be
reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_15"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This prospectus supplement contains forward-looking statements within the meaning of the federal securities laws. We make such
forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148;
&#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;assume&#148; and other expressions that predict or indicate
future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These
risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize, market and achieve market acceptance of SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron) extended-release injection (&#147;SUSTOL&#148;), CINVANTI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (aprepitant) injectable emulsion (&#147;CINVANTI&#148;) and future product candidates, including our positioning relative to competing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the outcome of the commercial launch of CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the <FONT STYLE="white-space:nowrap">HTX-011</FONT> Phase 2 and Phase 3 study results are indicative of the results in future studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of the New Drug Application (&#147;NDA&#148;) submission to the U.S. Food and Drug Administration (&#147;FDA&#148;) for <FONT STYLE="white-space:nowrap">HTX-011</FONT> and potential regulatory approval for
and commercial launch of <FONT STYLE="white-space:nowrap">HTX-011;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market opportunities for SUSTOL, CINVANTI and <FONT STYLE="white-space:nowrap">HTX-011;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors&#146; activities, including decisions as to the timing of competing product launches, generic entrants, pricing and discounting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical studies and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, potential regulatory approval or
further development of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical studies, and our ability to submit for and obtain regulatory approval for product candidates, in our anticipated
timing, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to meet the postmarketing study requirements within the FDA&#146;s mandated timelines and to obtain favorable results and comply with standard postmarketing requirements including U.S. federal advertising
and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy and security laws, safety information, safety surveillance and disclosure of payments or other transfers of value to healthcare professionals and
entities for SUSTOL, CINVANTI or any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sustained-release
drug delivery technology (&#147;Biochronomer technology&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations and vendor relationships for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or products we may acquire; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints or changes in the regulatory environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third-party infringement claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus supplement reflect our current views with respect to future events or to our future
financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; in this prospectus, the
accompanying prospectus supplement and elsewhere in documents incorporated by reference herein. You should carefully review all of these factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
These forward-looking statements were based on information, plans and estimates as of the date of this prospectus supplement, and except as required by law, we assume no obligation to update any forward-looking statements to reflect changes in
underlying assumptions or factors, new information, future events or other changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement may also contain
estimates, projections and other information concerning our industry, our business and the markets for certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections,
market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_16"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary of our business highlights certain of the information contained elsewhere in or incorporated by reference into this
prospectus supplement and the accompanying prospectus. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying
prospectus, including the documents incorporated by reference, which are described under &#147;Information Incorporated By Reference&#148; and &#147;Where You Can Find Additional Information&#148; in the accompanying prospectus. In particular, you
should carefully consider the matters discussed in the section of this prospectus supplement titled &#147;Risk Factors&#148; and in the accompanying prospectus and periodic reports incorporated herein by reference. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
biotechnology company focused on improving the lives of patients by developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatments to address some of the most important unmet patient needs. We are
developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2016, our first commercial product, SUSTOL, was approved by the FDA. SUSTOL is indicated in combination with other
antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (&#147;MEC&#148;) or anthracycline and cyclophosphamide (&#147;AC&#148;) combination
chemotherapy regimens. SUSTOL is an extended-release, injectable <FONT STYLE="white-space:nowrap">5-HT</FONT><SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonist that utilizes Heron&#146;s Biochronomer<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> polymer-based drug delivery technology to maintain therapeutic levels of granisetron for <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5&nbsp;days. We commenced commercial sales of SUSTOL in the
U.S. in October 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2017, our second commercial product, CINVANTI, was approved by the FDA. CINVANTI, in
combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (&#147;HEC&#148;), including high-dose
cisplatin and nausea and vomiting associated with initial and repeat courses of MEC. CINVANTI is an intravenous formulation of aprepitant, a substance <FONT STYLE="white-space:nowrap">P/neurokinin-1</FONT> (&#147;NK<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148;) receptor antagonist. CINVANTI is the only IV formulation of an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist indicated for the prevention of acute and
delayed nausea and vomiting associated with HEC and nausea and vomiting associated with MEC that is free of polysorbate 80 or any other synthetic surfactant. We commenced commercial sales of CINVANTI in the U.S. in January 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011,</FONT> which utilizes Heron&#146;s proprietary Biochronomer<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> polymer-based drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory
meloxicam for the management of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, <FONT STYLE="white-space:nowrap">HTX-011</FONT> was designed to
deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2018, Heron reported positive topline results from EPOCH1 and EPOCH2, its pivotal Phase&nbsp;3 studies of <FONT
STYLE="white-space:nowrap">HTX-011</FONT> in bunionectomy and hernia repair, respectively. All primary and key secondary endpoints were achieved in these studies. Furthermore, <FONT STYLE="white-space:nowrap">HTX-011</FONT> is the only long-acting
local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use compared to bupivacaine solution, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> local
anesthetic for postoperative pain control, through 72&nbsp;hours. <FONT STYLE="white-space:nowrap">HTX-011</FONT> was well tolerated in both studies, with a safety profile comparable to placebo and bupivacaine solution. In June 2018, Heron reported
positive topline results from its Phase&nbsp;2b studies of <FONT STYLE="white-space:nowrap">HTX-011</FONT> in subjects undergoing total knee arthroplasty and </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breast augmentation. <FONT STYLE="white-space:nowrap">HTX-011</FONT> was granted Fast Track designation by the FDA in the fourth quarter of 2017 and Breakthrough Therapy designation by the FDA in
the second quarter of 2018. In the second half of 2018, Heron expects to submit an NDA to the FDA for <FONT STYLE="white-space:nowrap">HTX-011.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CINV Product Portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SUSTOL </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL was our first commercial product. SUSTOL was approved by the FDA on August&nbsp;9, 2016, and we commenced commercial sales in the U.S.
in October 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and
vomiting associated with initial and repeat courses of MEC or AC combination chemotherapy regimens. SUSTOL is an extended-release, injectable <FONT STYLE="white-space:nowrap">5-hydroxytryptamine</FONT> type&nbsp;3
<FONT STYLE="white-space:nowrap">(&#147;5-HT</FONT><SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>&#148;) receptor antagonist that utilizes our Biochronomer technology to maintain therapeutic levels of granisetron for <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5&nbsp;days. The SUSTOL global Phase&nbsp;3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#146;s efficacy and safety in more than 2,000 patients with
cancer. SUSTOL&#146;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase <FONT STYLE="white-space:nowrap">(0-24&nbsp;hours</FONT> following chemotherapy) and the delayed phase
<FONT STYLE="white-space:nowrap">(24-120&nbsp;hours</FONT> following chemotherapy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is the first extended-release <FONT
STYLE="white-space:nowrap">5-HT</FONT><SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and AC combination chemotherapy
regimens. A standard of care in the treatment of breast cancer and other cancer types, AC regimens are among the most commonly prescribed HEC regimens, as defined by both the National Comprehensive Cancer Network (&#147;NCCN&#148;) and the American
Society of Clinical Oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, the NCCN included SUSTOL as a part of its NCCN Clinical Practice Guidelines in Oncology
for Antiemesis Version 1.2017. The NCCN has given SUSTOL a Category 1 recommendation, the highest level category of evidence and consensus, for use in the prevention of acute and delayed nausea and vomiting in patients receiving HEC or MEC regimens.
The guidelines now identify SUSTOL as a &#147;preferred&#148; agent for preventing nausea and vomiting following MEC. Further, the guidelines highlight the unique, extended-release formulation of SUSTOL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, a product-specific billing code, or permanent <FONT STYLE="white-space:nowrap">J-code</FONT>
<FONT STYLE="white-space:nowrap">(&#147;J-code&#148;),</FONT> for SUSTOL became available. The <FONT STYLE="white-space:nowrap">J-code</FONT> was assigned by the&nbsp;Centers for Medicare and Medicaid Services and will help simplify the billing and
reimbursement process for prescribers of SUSTOL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CINVANTI </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CINVANTI is our second commercial product. CINVANTI was approved by the FDA on November&nbsp;9, 2017, and we commenced commercial sales in the
U.S. in January 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and
delayed nausea and vomiting associated with initial and repeat courses of HEC including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of MEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CINVANTI is an intravenous formulation of aprepitant, an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist.
CINVANTI is the first intravenous (&#147;IV&#148;) formulation to directly deliver aprepitant, the active ingredient in EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> capsules. Aprepitant (including its prodrug, fosaprepitant) is
the only single-agent NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist to significantly </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduce nausea and vomiting in both the acute phase (0&nbsp;&#150;&nbsp;24&nbsp;hours after chemotherapy) and the delayed phase (24&nbsp;&#150;&nbsp;120&nbsp;hours after chemotherapy). CINVANTI is
the only IV formulation of an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with HEC and nausea and vomiting associated with MEC that
is free of polysorbate 80 or any other synthetic surfactant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor
antagonists are typically used in combination with <FONT STYLE="white-space:nowrap">5-HT3</FONT> receptor antagonists. The only other injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist currently approved in
the U.S. for both acute and delayed CINV, EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> IV (fosaprepitant), contains polysorbate&nbsp;80, a synthetic surfactant, which has been linked to hypersensitivity reactions, including
anaphylaxis, and infusion site reactions. The CINVANTI formulation does not contain polysorbate&nbsp;80 or any other synthetic surfactant. Our CINVANTI data has demonstrated the bioequivalence of CINVANTI to EMEND IV, supporting its efficacy for the
prevention of both acute and delayed nausea and vomiting associated with HEC and nausea and vomiting associated with MEC. Results also showed CINVANTI was better tolerated in healthy volunteers than EMEND IV, with significantly fewer adverse events
reported with CINVANTI. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pain Management Product Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">HTX-011</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011,</FONT> which utilizes our Biochronomer technology, is an investigational, long-acting,
extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local
anti-inflammatory agent directly to the site of tissue injury, <FONT STYLE="white-space:nowrap">HTX-011</FONT> was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which
carry the risk of harmful side effects, abuse and addiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we reported positive topline results from two completed
Phase&nbsp;2b studies of <FONT STYLE="white-space:nowrap">HTX-011:</FONT> Study 209 (local administration in total knee arthroplasty) and Study 211 (instillation or pectoral pocket nerve block in breast augmentation).
<FONT STYLE="white-space:nowrap">HTX-011</FONT> achieved the primary endpoints in both studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Total Knee Arthroplasty&nbsp;&#151; Study 209 Results
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Study 209 was a randomized, placebo- and active-controlled, double-blind, Phase&nbsp;2b clinical study in patients undergoing primary
unilateral total knee arthroplasty to evaluate the analgesic efficacy, safety and pharmacokinetics of locally administered <FONT STYLE="white-space:nowrap">HTX-011</FONT> into the surgical site. Following a dose-escalation phase, 222 patients were
randomized to receive: <FONT STYLE="white-space:nowrap">(1)&nbsp;HTX-011</FONT> 400&nbsp;mg administered via instillation into the surgical site <FONT STYLE="white-space:nowrap">(HTX-011</FONT> alone);
<FONT STYLE="white-space:nowrap">(2)&nbsp;HTX-011</FONT> 400&nbsp;mg administered via instillation into the surgical site with a low dose of ropivacaine injected into the posterior capsule <FONT STYLE="white-space:nowrap">(HTX-011</FONT>
combination); (3)&nbsp;bupivacaine 125&nbsp;mg administered via multiple injections into the surgical site; and (4)&nbsp;placebo. Ropivacaine and bupivacaine are generically available
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> local anesthetics used in the management of postoperative pain. This study included a <FONT STYLE="white-space:nowrap">pre-specified</FONT> hierarchical
testing strategy for the primary and key secondary endpoints for the <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg treatment groups. The primary endpoint was pain intensity as measured by the Area Under the Curve (&#147;AUC&#148;) from
0 to 48&nbsp;hours post-surgery (&#147;AUC <FONT STYLE="white-space:nowrap">0-48&#148;)</FONT> for <FONT STYLE="white-space:nowrap">HTX-011</FONT> compared to placebo. The key secondary endpoint was pain intensity as measured by the AUC from 0 to
72&nbsp;hours post-surgery (&#147;AUC <FONT STYLE="white-space:nowrap">0-72&#148;)</FONT> for <FONT STYLE="white-space:nowrap">HTX-011</FONT> compared to placebo. The primary and key secondary endpoints were achieved: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">HTX-011</FONT> combination and <FONT STYLE="white-space:nowrap">HTX-011</FONT> alone resulted in reductions of 23% and 19%, respectively, in pain intensity measured at rest through
48&nbsp;hours when compared to placebo (p&lt;0.0001 and p=0.0002, respectively). These pain reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were approximately double that of bupivacaine, which resulted in a reduction of 11%. The <FONT
STYLE="white-space:nowrap">HTX-011</FONT> combination reduction was significantly better than that of bupivacaine (p=0.0212). </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">HTX-011</FONT> combination and <FONT STYLE="white-space:nowrap">HTX-011</FONT> alone resulted in reductions of 22% and 19%, respectively, in pain intensity measured at rest through
72&nbsp;hours when compared to placebo (p&lt;0.0001 and p=0.0004, respectively). These pain reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were also approximately double that of bupivacaine, which resulted in a reduction of 11%. The
<FONT STYLE="white-space:nowrap">HTX-011</FONT> combination reduction was significantly better than that of bupivacaine through 72&nbsp;hours (p=0.0325). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">With the more conservative assessment of pain with activity, the <FONT STYLE="white-space:nowrap">HTX-011</FONT> combination and <FONT STYLE="white-space:nowrap">HTX-011</FONT> alone resulted in reductions of 16% and
12%, respectively, in pain intensity measured with activity through 48&nbsp;hours when compared to placebo (p&lt;0.0001 and p=0.0017, respectively). These pain reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were significantly better
than that of bupivacaine, which resulted in a reduction of 4% (p=0.0012 and p=0.0366, respectively). Both the <FONT STYLE="white-space:nowrap">HTX-011</FONT> combination and <FONT STYLE="white-space:nowrap">HTX-011</FONT> alone maintained control of
pain with activity through 72&nbsp;hours with a 15% (p=0.0002) and 11% (p=0.0058) reduction compared to placebo, respectively. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">HTX-011</FONT> combination significantly reduced opioid use through 48 and 72&nbsp;hours compared to placebo (p=0.0091 and p=0.0253, respectively). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Breast Augmentation&nbsp;&#151; Study&nbsp;211 Results </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Study 211 was a randomized, placebo- and active-controlled, double-blind, Phase&nbsp;2b dose-finding study in patients undergoing augmentation
mammoplasty to evaluate the analgesic efficacy, safety and pharmacokinetics of <FONT STYLE="white-space:nowrap">HTX-011</FONT> when administered by instillation into the surgical site or via ultrasound-guided lateral and medial pectoral nerve block
before surgery. The study consisted of three cohorts comparing <FONT STYLE="white-space:nowrap">HTX-011</FONT> nerve block (60&nbsp;mg, 120&nbsp;mg, 240&nbsp;mg) to the standard dose of bupivacaine 50&nbsp;mg, administered as a nerve block, and
placebo, and a final cohort comparing both <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg administered by instillation and <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg administered as a nerve block to the same two control
groups. A total of 243 patients were enrolled. The primary endpoint was pain intensity as measured by the AUC from 0 to 24&nbsp;hours post-surgery (&#147;AUC <FONT STYLE="white-space:nowrap">0-24&#148;)</FONT> compared to placebo. The primary
endpoint of the study was achieved: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg administered by instillation into the surgical site and <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg administered as a nerve block both resulted
in reductions of 22% in pain intensity measured at rest through 24&nbsp;hours when compared to placebo (p=0.0023 and p=0.0055, respectively). These pain reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were approximately triple that
of bupivacaine administered as a nerve block, which resulted in a reduction of 8%. The <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg instillation reduction was significantly better than that of bupivacaine (p=0.0383).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">With the more conservative assessment of pain with activity, <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400 mg instillation and <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg nerve block resulted in
reductions of 24% and 23%, respectively, in pain intensity measured with activity through 24&nbsp;hours when compared to placebo (p=0.0004 and p=0.0015, respectively). These pain reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were
approximately double that of bupivacaine administered as a nerve block, which resulted in a reduction of 12%. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">HTX-011</FONT> 400&nbsp;mg instillation and <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400 mg nerve block resulted in reductions in total opioid use of 33% and 26%, respectively,
when compared to placebo (p=0.0093 and p=0.0435, respectively). These reductions from <FONT STYLE="white-space:nowrap">HTX-011</FONT> were approximately triple that of bupivacaine administered as a nerve block, which resulted in a reduction of 10%.
The <FONT STYLE="white-space:nowrap">HTX-011</FONT> 400 mg instillation reduction was significantly better than that of bupivacaine (p=0.0455). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was a strong correlation between pain reduction and the pharmacokinetics of <FONT STYLE="white-space:nowrap">HTX-011</FONT> in both
studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011</FONT> was well tolerated in both studies, with a safety profile comparable to placebo
and bupivacaine solution. There were no deaths and no clinically meaningful differences in overall adverse events, serious </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse events, premature discontinuations due to adverse events, potential local anesthetic systemic toxicity related adverse events or wound healing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we announced that we have been granted Breakthrough Therapy designation for <FONT STYLE="white-space:nowrap">HTX-011</FONT> by
the FDA for postoperative pain management. Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat serious conditions and for which preliminary clinical evidence indicates substantial
improvement over available therapies on clinically significant endpoint(s). Breakthrough Therapy designation was granted for <FONT STYLE="white-space:nowrap">HTX-011</FONT> based on the results of Phase&nbsp;2 studies and two recently completed
Phase&nbsp;3 studies, which showed that <FONT STYLE="white-space:nowrap">HTX-011</FONT> produced significant reductions in both pain intensity and the need for opioids through 72&nbsp;hours post-surgery compared to placebo and bupivacaine solution,
the standard of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2018, we reported positive topline results from EPOCH1 and EPOCH2, our pivotal Phase&nbsp;3 studies of <FONT
STYLE="white-space:nowrap">HTX-011</FONT> in bunionectomy and hernia repair, respectively. All primary and key secondary endpoints were achieved in these studies. Furthermore, <FONT STYLE="white-space:nowrap">HTX-011</FONT> is the only long-acting
local anesthetic to demonstrate in Phase&nbsp;3 studies significantly reduced pain and opioid use compared to bupivacaine solution, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> local
anesthetic for postoperative pain control, through 72&nbsp;hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary and key secondary endpoints for both Phase&nbsp;3 studies
were identical. The primary endpoint was pain intensity as measured by the <FONT STYLE="white-space:nowrap">AUC&nbsp;0-72</FONT> compared to placebo. Key secondary endpoints in order of evaluation were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">comparison of AUC <FONT STYLE="white-space:nowrap">0-72</FONT> of pain intensity to bupivacaine solution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total amount of opioid rescue medication consumption compared to placebo through 72&nbsp;hours post-surgery; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proportion of patients who received no opioid rescue medication post-surgery compared to bupivacaine solution; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total opioid consumption through 72&nbsp;hours post-surgery compared to bupivacaine. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Bunionectomy&nbsp;&#151; Study&nbsp;301/EPOCH1 Results </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EPOCH1 was a randomized, placebo- and active-controlled, double-blind, Phase&nbsp;3 clinical study evaluating the efficacy and safety of
locally administered <FONT STYLE="white-space:nowrap">HTX-011</FONT> at 60&nbsp;mg compared to the standard dose of bupivacaine solution (50&nbsp;mg) and placebo for post-operative pain control following bunionectomy surgery in 412 subjects. All
primary and key secondary endpoints were achieved: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There was a 27% reduction in pain intensity as measured by AUC <FONT STYLE="white-space:nowrap">0-72</FONT> when comparing <FONT STYLE="white-space:nowrap">HTX-011</FONT> to placebo (p&lt;0.0001); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There was an 18% reduction in pain as measured by AUC <FONT STYLE="white-space:nowrap">0-72</FONT> when comparing <FONT STYLE="white-space:nowrap">HTX-011</FONT> to bupivacaine solution (p=0.0002); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over 72 hours post-surgery, patients receiving <FONT STYLE="white-space:nowrap">HTX-011</FONT> consumed 37% less opioids than placebo patients (p&lt;0.0001) and 25% less opioids than patients receiving bupivacaine
solution (p=0.0022); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">29% of patients receiving <FONT STYLE="white-space:nowrap">HTX-011</FONT> required no opioid medication for 72&nbsp;hours post-surgery compared to only 2% receiving placebo (p&lt;0.0001) and 11% receiving the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> bupivacaine solution (p=0.0001). These results parallel the significantly reduced incidence of severe pain in patients receiving <FONT
STYLE="white-space:nowrap">HTX-011</FONT> compared to both placebo (36% reduction; p&lt;0.0001) and bupivacaine (29% reduction; p&lt;0.0001). </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Hernia Repair &#151; Study 302/EPOCH2 Results </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EPOCH2 was a randomized, placebo- and active-controlled, double-blind, Phase 3 clinical study evaluating the efficacy and safety of locally
administered <FONT STYLE="white-space:nowrap">HTX-011</FONT> at 300 mg compared to the standard dose of bupivacaine solution (75 mg) and placebo for post-operative pain control following hernia repair surgery in 418 subjects. All primary and key
secondary endpoints were achieved: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There was a 23% reduction in pain intensity as measured by AUC <FONT STYLE="white-space:nowrap">0-72</FONT> when comparing <FONT STYLE="white-space:nowrap">HTX-011</FONT> to placebo (p=0.0004); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There was a 21% reduction in pain as measured by AUC <FONT STYLE="white-space:nowrap">0-72</FONT> when comparing <FONT STYLE="white-space:nowrap">HTX-011</FONT> to bupivacaine solution (p&lt;0.0001); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over 72 hours post-surgery, patients receiving <FONT STYLE="white-space:nowrap">HTX-011</FONT> consumed 38% less opioids than placebo patients (p=0.0001) and 25% less opioids than patients receiving bupivacaine solution
(p=0.0240); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">51% of patients receiving <FONT STYLE="white-space:nowrap">HTX-011</FONT> required no opioid medication for 72 hours post-surgery compared to only 22% receiving placebo (p&lt;0.0001) and 40% receiving the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> bupivacaine solution (p=0.0486). These results parallel the significantly reduced incidence of severe pain in patients receiving <FONT
STYLE="white-space:nowrap">HTX-011</FONT> compared to both placebo (40% reduction; p&lt;0.0001) and bupivacaine (19% reduction; p=0.0372). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011</FONT> was well tolerated in both studies, with a safety profile comparable to placebo and
bupivacaine solution. There were no drug-related serious adverse events or discontinuations due to drug-related adverse events in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HTX-011-treated</FONT></FONT> patients, and there
were fewer opioid-related adverse events in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HTX-011-treated</FONT></FONT> patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011</FONT> is the only long-acting anesthetic designed to address both postoperative pain and
inflammation in a single administration at the surgical site. The unique synergy of bupivacaine and meloxicam in <FONT STYLE="white-space:nowrap">HTX-011</FONT> has consistently been shown to reduce pain over 72 hours significantly better than
bupivacaine alone in multiple diverse surgical models. <FONT STYLE="white-space:nowrap">HTX-011</FONT> is administered as a single-dose application via needle-free syringe to directly coat the affected tissue within the surgical site prior to
suturing, which makes <FONT STYLE="white-space:nowrap">HTX-011&#146;s</FONT> route of administration faster, easier and potentially safer compared to numerous injections required with current local anesthetics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we announced that we have been granted Fast Track designation for <FONT STYLE="white-space:nowrap">HTX-011</FONT> by the FDA
for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72&nbsp;hours. Fast Track designation is intended to facilitate the development and expedite the review of new therapies to treat
serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biochronomer
Technology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary Biochronomer technology is designed to deliver therapeutic levels of a wide range of otherwise
short-acting pharmacological agents over a period from days to weeks with a single administration. Our Biochronomer technology consists of bioerodible polymers that have been the subject of comprehensive animal and human toxicology studies that have
shown evidence of the safety of the polymer. When administered, the polymers undergo controlled hydrolysis, resulting in a controlled, sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition.
Furthermore, our Biochronomer technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a single administration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have executive
offices located at 4242&nbsp;Campus Point Court, Suite&nbsp;200, San Diego, California 92121, and our telephone number is <FONT STYLE="white-space:nowrap">(858)&nbsp;251-4400.</FONT> Our website address is<I> www.herontx.com.</I> We make our
periodic </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and current reports available on our website, free of charge, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. No portion of our
website is incorporated by reference into this prospectus supplement. The Company files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document filed by the Company at the
SEC&#146;s Public Reference Room at 100&nbsp;F&nbsp;Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT>
for further information on the public reference room. The Company&#146;s filings with the SEC are also available to the public on the SEC&#146;s web site at<I> http://www.sec.gov</I>. Additional information regarding the Company, including our
audited financial statements and descriptions of our business, is contained in the documents incorporated by reference in this prospectus supplement. See &#147;Information Incorporated by Reference&#148; and &#147;Where You Can Find Additional
Information&#148; in this prospectus supplement and the accompanying prospectus. Our common stock is listed on The Nasdaq Capital Market under the symbol &#147;HRTX.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_17"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock We Are Offering Pursuant to this Prospectus Supplement </P></TD>
<TD>5,063,292 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Outstanding after this Offering </P></TD>
<TD>70,107,490 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to Purchase Additional Shares </P></TD>
<TD>We have granted the underwriter an option for a period of 30&nbsp;days from the date of this prospectus supplement to purchase up to 759,493 additional shares of common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering for the commercial launch of <FONT STYLE="white-space:nowrap">HTX-011,</FONT> if approved by the FDA, the continued commercialization and marketing of SUSTOL and CINVANTI, our ongoing and
future clinical trials, including further clinical studies for <FONT STYLE="white-space:nowrap">HTX-011,</FONT> preclinical development work, other product development activities and general corporate purposes. See &#147;Use of Proceeds.&#148;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">The Nasdaq Capital Market Symbol </P></TD>
<TD>&#147;HRTX&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>This investment involves a high degree of risk. You should read the &#147;Risk Factors&#148; section of this prospectus supplement and the accompanying prospectus and our most recent Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> incorporated by reference herein, for a discussion of factors to consider carefully before deciding to
invest in shares of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock shown above to be outstanding after this
offering is based on the 65,044,198&nbsp;shares outstanding as of March&nbsp;31, 2018 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">12,905,851&nbsp;shares of our common stock subject to options outstanding as of March&nbsp;31, 2018 having a weighted average exercise price of $15.22&nbsp;per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,807,736&nbsp;shares of our common stock that have been reserved for issuance in connection with future grants under our Amended and Restated 2007&nbsp;Equity Plan (the &#147;2007&nbsp;Plan&#148;) as of March&nbsp;31,
2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">267,317&nbsp;shares of our common stock that have been reserved for issuance under our Employee Stock Purchase Plan (&#147;ESPP&#148;) as of March&nbsp;31, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">640,164&nbsp;shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants as of March&nbsp;31, 2018, having a weighted average exercise price of $1.14&nbsp;per share; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,102,702&nbsp;shares of common stock issuable upon the conversion of outstanding principal due under outstanding secured convertible promissory notes as of March&nbsp;31, 2018. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriter&#146;s option to purchase additional shares is exercised in full, we will issue and sell an additional 759,493 shares of
our common stock and will have 70,866,983 shares outstanding after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, all information in this
prospectus supplement assumes no exercise of the underwriter&#146;s option to purchase additional shares of common stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_18"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
consider carefully the risks described below and discussed under the sections captioned &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and any
subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein in their entirety, together with other information contained in or incorporated by reference in this prospectus supplement
and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or prospects could be seriously harmed. This could
cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Topline data may not accurately reflect the complete results of a particular study or trial. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may publicly disclose preliminary or topline data from our clinical studies such as the recent topline results for our clinical trials of <FONT
STYLE="white-space:nowrap">HTX-011,</FONT> which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit
and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate
or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may
be harmed, which could harm our business, operating results, prospects or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A Fast Track designation by the FDA may not actually
lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011</FONT> has been
granted a Fast Track designation from the FDA for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours. Fast Track designation is intended to facilitate the development and expedite
the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions with the FDA. Obtaining a Fast Track designation does not change the standards for product
approval, but may expedite the development or approval process. Even though the FDA has granted such designation for <FONT STYLE="white-space:nowrap">HTX-011,</FONT> it may not actually result in faster clinical development or regulatory review or
approval. Furthermore, such a designation does not increase the likelihood that <FONT STYLE="white-space:nowrap">HTX-011</FONT> will receive marketing approval in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Breakthrough Therapy designation from the FDA may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that <FONT STYLE="white-space:nowrap">HTX-011</FONT> will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011</FONT> has been granted breakthrough therapy designation from the FDA for postoperative pain
management. Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat serious conditions and for which preliminary clinical evidence indicates substantial improvement over available
therapies on clinically significant endpoint(s). The receipt of a breakthrough therapy designation for <FONT STYLE="white-space:nowrap">HTX-011</FONT> may not result in a faster development process, review or approval compared to drugs considered
for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even though the FDA granted breakthrough designation, the FDA may later decide that <FONT STYLE="white-space:nowrap">HTX-011</FONT> no
longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to this
Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds to us from this offering; we may not use the offering proceeds that we
receive effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds to us from this offering,
including for any of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of
the number and variability of factors that will determine our use of the net proceeds to us from this offering, their ultimate use may vary from their currently intended use. The failure by our management to apply these funds effectively could harm
our business. Pending their use, we may invest the net proceeds to us from this offering in investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. See &#147;Use of Proceeds.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_19"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of the shares of common stock that we are offering will be approximately $194.7 million, or
approximately $223.9 million if the underwriter exercises in full its option to purchase up to 759,493 additional shares of common stock, after deducting the underwriting discounts, but before deducting estimated offering expenses payable by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for the commercial launch of <FONT STYLE="white-space:nowrap">HTX-011,</FONT> if
approved by the FDA, the continued commercialization and marketing of SUSTOL and CINVANTI, our ongoing and future clinical trials, including further clinical studies for <FONT STYLE="white-space:nowrap">HTX-011,</FONT> preclinical development work,
other product development activities and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the net proceeds, we intend to invest the net
proceeds in short-term, interest-bearing, investment-grade securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an underwriting agreement with Jefferies LLC with respect to the shares of common stock being offered hereby. Subject to
the terms and conditions set forth in an underwriting agreement among us and the underwriter, the underwriter has agreed to purchase from us 5,063,292 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriter has agreed to purchase all of the shares sold
under the underwriting agreement if any of these shares are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriter against certain
liabilities, including liabilities under the Securities Act of 1933, as amended, and to contribute to payments the underwriter may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter is offering the shares, subject to prior sale, when, as and if issued to and accepted by it, subject to approval of legal
matters by its counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriter of officer&#146;s certificates and legal opinions. The underwriter reserves the right
to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has agreed to purchase 5,063,292 shares of our common stock at a price of $38.445 per share, which will result in approximately
$194.7&nbsp;million of net proceeds to us before deducting estimated offering expenses payable by us. The underwriter may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage
transactions on The Nasdaq Capital Market, or to dealers in negotiated transactions, or in a combination of such methods of sale or otherwise, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at
prices related to such prevailing market prices or at negotiated prices. The difference between the price at which the underwriter purchases shares from us and the price at which the underwriter resells such shares may be deemed underwriting
compensation. If the underwriter effects such transactions by selling shares of common stock to or through dealers, such dealers may receive compensation in the form of discounts or concessions from the underwriter and/or purchasers of shares of
common stock for whom they may act as agents or to whom they may sell as principal. The expenses of the offering, not including the underwriting discounts, are estimated at $230,000 and are payable by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have granted an option to the underwriter, exercisable for 30 days after the date of this prospectus supplement, to purchase up to 759,493 additional shares from us at a price of $38.445 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of
<FONT STYLE="white-space:nowrap">Rule&nbsp;16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter
owned either of record or beneficially, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce an intention to do any of the foregoing for a period of 90&nbsp;days after the date of this prospectus supplement without the prior written consent of Jefferies LLC. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the common stock on and including
the 90th day after the date of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies LLC may, in its sole discretion and at any time or from time to time
before the termination of the <FONT STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Except for customary <FONT
STYLE="white-space:nowrap">lock-up</FONT> exceptions, including an exception allowing our directors and officers to make sales under preexisting <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, there are no existing agreements between the
underwriter and any of our shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period;
provided however, that the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for Kevin Tang, the Chairman of our Board of Directors, permits him to make gifts of securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement without requiring the recipient of such securities to execute a similar <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Nasdaq Capital Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares are listed on The Nasdaq Capital Market under the symbol &#147;HRTX.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit the underwriter from bidding for and purchasing our common stock.
However, the underwriter may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriter of a greater number of shares than it is required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriter&#146;s option to purchase additional shares described above. The underwriter may close out any covered short position by either exercising its option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriter will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriter must close out any naked short position by purchasing shares
in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who
purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriter in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriter may conduct these transactions on The Nasdaq Capital Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. In addition, neither we nor the underwriter make any representation that it will engage in these transactions or that these transactions, once commenced, will not be discontinued without
notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Market Making </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this Offering, the underwriter may also engage in passive market making transactions in our common stock on The Nasdaq Capital Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Act during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker
must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are
exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriter is not required to engage in passive market
making and, if commenced, may end passive market making activities at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter may distribute this prospectus supplement and the accompanying prospectus by electronic means,
such as <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter and its affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the
ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriter and its affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares
of common stock which are the subject of the offering has been, or will be made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriter for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares of common stock referred to in (a)&nbsp;to (c)&nbsp;above shall result in a requirement for the Company or the underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant
to Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares of common stock is made or
who receives any communication in respect of any offer of ordinary shares, or who initially acquires any shares of common stock will be deemed to have represented, warranted, acknowledged and agreed to and with the underwriter and the Company that
(1)&nbsp;it is a &#147;qualified investor&#148; within the meaning of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares of common stock acquired by it as a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares of common stock acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons
in any Member State other than qualified investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the underwriter has been given to the offer or resale; or where ordinary shares have been
acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those ordinary shares to it is not treated under the Prospectus Directive as having been made to such persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the underwriter and their respective affiliates will rely upon the truth and
accuracy of the foregoing representations, acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement has been prepared on the basis that
any offer of shares of common stock in any Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares of common stock. Accordingly, any person making or
intending to make an offer in that Member State of shares of common stock which are the subject of the offering contemplated in this prospectus supplement may only do so in circumstances in which no obligation arises for the Company or the
underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Company nor the underwriter have authorized, nor do they authorize, the making of any offer of shares of common stock in
circumstances in which an obligation arises for the Company or the underwriter to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes
of this provision, the expression an &#147;offer of shares of common stock to the public&#148; in relation to any shares of common stock in any Member State means the communication in any form and by any means of sufficient information on the terms
of the offer and the shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe the shares of common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive
in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005, as amended (&#147;Order&#148;), and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of
the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or
investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in Switzerland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange
(&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or
otherwise made publicly available in Switzerland. Neither this document nor any other offering or marketing material relating to the offering, us or the shares has been or will be filed with or approved by any Swiss regulatory authority. In
particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act
on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an Exempt Offer in accordance with the Offered Securities Rules of the
Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus supplement and the accompanying prospectus are intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. They must not be
delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement and the accompanying prospectus nor taken
steps to verify the information set forth therein and has no responsibility for this prospectus supplement and the accompanying prospectus. The shares to which this prospectus supplement and the accompanying prospectus relate may be illiquid and/or
subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus supplement and the accompanying prospectus you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission, in relation to the offering. This prospectus supplement and the accompanying prospectus do not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001
(&#147;Corporations Act&#148;), and do not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (Exempt Investors) who are &#147;sophisticated investors&#148; (within the
meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act
so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied for
by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying
prospectus contain general information only and do not take account of the investment objectives, financial situation or particular needs of any particular person. They do not contain any securities recommendations or financial product advice.
Before making an investment decision, investors need to consider whether the information in this prospectus supplement and the accompanying prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice
on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be
disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus supplement and the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the
shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and
Futures Act, Chapter 289 of Singapore (&#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA,
or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the
shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever
described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement constitutes an &#147;exempt offering document&#148; as defined in and for the purposes of applicable Canadian
securities laws. No prospectus has been filed with any securities commission or similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authority in Canada in connection with the offer and sale of the common stock. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon
this prospectus supplement or on the merits of the common stock and any representation to the contrary is an offence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Canadian
investors are advised that this prospectus supplement has been prepared in reliance on section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (&#147;NI
<FONT STYLE="white-space:nowrap">33-105&#148;).</FONT> Pursuant to section 3A.3 of NI <FONT STYLE="white-space:nowrap">33-105,</FONT> this prospectus supplement is exempt from the requirement that the Company and the underwriter provide investors
with certain conflicts of interest disclosure pertaining to &#147;connected issuer&#148; and/or &#147;related issuer&#148; relationships that may exist between the Company and the underwriter as would otherwise be required pursuant to subsection
2.1(1) of NI <FONT STYLE="white-space:nowrap">33-105.</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement that the
Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary
depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus
requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the
common stock outside of Canada. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Canadian investor who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that the
investor (i)&nbsp;is purchasing the common stock as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&nbsp;is an
&#147;accredited investor&#148; as such term is defined in section 1.1 of National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> (&#147;NI <FONT STYLE="white-space:nowrap">45-106&#148;)</FONT> or, in Ontario,
as such term is defined in section 73.3(1) of the <I>Securities Act</I> (Ontario); and (iii)&nbsp;is a &#147;permitted client&#148; as such term is defined in section 1.1 of National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT>
<I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive
description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as
to the tax consequences to a resident, or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common stock for investment by such investor under relevant Canadian federal and provincial
legislation and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rights of Action for Damages or Rescission </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum
(such as this prospectus supplement), including where the distribution involves an &#147;eligible foreign security&#148; as such term is defined in Ontario Securities Commission Rule <FONT STYLE="white-space:nowrap">45-501</FONT> <I>Ontario
Prospectus and Registration Exemptions</I> and in Multilateral Instrument <FONT STYLE="white-space:nowrap">45-107</FONT> <I>Listing Representation and Statutory Rights of Action Disclosure Exemptions</I>, as applicable, with a remedy for damages or
rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &#147;misrepresentation&#148; as
defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian securities
legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Language of Documents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating
in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. <I>Par la r&eacute;ception de ce document, chaque investisseur Canadien
confirme par les pr&eacute;sentes qu&#146;il a express&eacute;ment exig&eacute; que tous les documents faisant foi ou se rapportant de quelque mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res d&eacute;crites aux
pr&eacute;sentes (incluant, pour plus de certitude, toute confirmation d&#146;achat ou tout avis) soient r&eacute;dig&eacute;s en anglais seulement.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, <FONT STYLE="white-space:nowrap">5728-1968,</FONT> or the
Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of common stock which are the subject of the
offering is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint
investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and
&#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for
the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP of San Francisco, California will pass on the validity of the shares of common stock offered hereby.
Latham&nbsp;&amp; Watkins LLP of San Diego, California is counsel to the underwriter in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OUM&nbsp;&amp; Co. LLP, an independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement.
Our consolidated financial statements are incorporated by reference in reliance on OUM&nbsp;&amp; Co. LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_23"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows the Company to &#147;incorporate by reference&#148; the information that is filed by the Company with the SEC, which means that
the Company can disclose important information to you by referring you to those documents. The documents incorporated by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information specifically incorporated by reference in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 from the Company&#146;s
Definitive Proxy Statement on Schedule&nbsp;14A relating to the Company&#146;s 2018 Annual Meeting of Stockholders, which was filed with the SEC on April&nbsp;30, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended March&nbsp;31, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;3, 2018, June&nbsp;22, 2018 and June&nbsp;25, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The description of the Company&#146;s common stock contained in Amendment No.&nbsp;3 to that certain registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on July&nbsp;6, 2017
pursuant to Section&nbsp;12 of the Exchange Act, including any amendment or report filed for the purpose of updating that description. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report
or documents that is not deemed filed under such provisions, on or after the date of this prospectus supplement until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which
this prospectus supplement is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus supplement and to be a part of this prospectus supplement from the date of filing of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded, for purposes of this prospectus supplement, to the extent that a statement contained in or omitted from this prospectus supplement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference
herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. Nothing in this prospectus supplement shall be
deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this
prospectus supplement is delivered, upon such person&#146;s written or oral request, a copy of any and all of the information incorporated by reference in this prospectus supplement, other than exhibits to such documents, unless such exhibits are
specifically incorporated by reference into the information that this prospectus supplement incorporates. Requests should be directed to the Secretary at Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, California 92121,
telephone number <FONT STYLE="white-space:nowrap">(858)&nbsp;251-4400.</FONT> You may also find these documents in the &#147;Investor Relations&#148; section of our website,<I> www.herontx.com</I>. The information on our website is not incorporated
into this prospectus supplement. We have authorized no one to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, you should not rely on any information that is not contained in this
prospectus supplement. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc631920_24"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual, quarterly and special
reports, proxy statements and other information with the SEC. You may read and copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public reference room. The Company&#146;s filings with the SEC are also available to the
public at the SEC&#146;s web site at<I> http://www.sec.gov</I>. Statements contained in this prospectus supplement as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of
the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g631920g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this prospectus, we or any selling stockholder may offer and sell from time to time, in one or more offerings, an indeterminate number
of shares of our common stock, preferred stock, and warrants or any combination thereof, separately, together or in series. The warrants may be convertible into or exercisable or exchangeable for common stock or preferred stock and the preferred
stock may be convertible into or exchangeable for common stock. Each time securities are offered or sold pursuant to this prospectus, we will describe in a prospectus supplement the securities being offered and sold, as well as the specific terms of
the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; On July&nbsp;5, 2017, the last
reported sale price on The NASDAQ Capital Market was $14.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any prospectus supplement and the
documents incorporated by reference in this prospectus and any prospectus supplement carefully before you invest. This prospectus may not be used to offer or sell any of our common stock, preferred stock or warrants unless accompanied by a
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer these securities in amounts, at prices and on terms determined at the time
of offering. We or any selling stockholder may sell the securities directly to investors, through agents we select, or through underwriters and dealers we select. See &#147;Plan of Distribution&#148; in this prospectus. Each prospectus supplement
will provide the amount, price, terms and plan of distribution relating to the securities to be sold pursuant to such prospectus supplement. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their
compensation in a prospectus supplement or sales agreement prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves certain risks. See &#147;<A HREF="#toc631920_4">Risk Factors</A>&#148; beginning on Page&nbsp;5 of this prospectus and in the applicable prospectus supplement and any related free writing prospectus, and in the other
documents that are incorporated by reference into this prospectus or the applicable prospectus supplement, for certain risks you should consider. You should read the entire prospectus carefully before you make your investment decision. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is July&nbsp;6, 2017 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_7">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_12">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc631920_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference into this prospectus and any
prospectus supplement or any free writing prospectus that we may provide to you. We have not authorized anyone to provide you with different information. You must not rely upon any unauthorized information or representation. You should not assume
that the information contained in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date on the front cover of the prospectus or the prospectus supplement or that the information contained in any
document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making
offers to sell the securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an
offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the Heron logo, SUSTOL<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, CINVANTI&#153; and Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks. All other trademarks appearing or incorporated by reference into this prospectus and
any applicable prospectus supplement are the property of their respective owners. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, as
a &#147;well-known seasoned issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we and/or selling stockholders may offer shares of our common stock
and preferred stock, various series of warrants to purchase common stock or preferred stock, or any combination thereof, from time to time in one or more offerings under this prospectus at prices and on terms to be determined by market conditions at
the time of offering. This prospectus only provides you with a general description of the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders offer a type or series of securities under this prospectus, we
will provide a prospectus supplement to this prospectus that will contain more specific information about the securities being offered and specific terms of the offering. We may also authorize one or more free writing prospectuses to be provided to
you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Each such prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. If there is any inconsistency between the information in this prospectus
and the applicable prospectus supplement or related free writing prospectus, you should rely on the prospectus supplement or any related free writing prospectus we may authorize to be provided to you. We urge you to carefully read this prospectus,
any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Information Incorporated by Reference&#148; and &#147;Where You Can
Find Additional Information&#148; before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized anyone to
provide you with information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the
reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as
of the date on the front of the document (unless the information specifically indicates that another date applies) and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference,
regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_2"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;assume&#148; and other expressions that predict or indicate future events and
trends and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties
and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize, market and achieve market acceptance of SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron) extended-release injection (&#147;SUSTOL&#148;) and for
future product candidates, including our positioning relative to competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the outcomes of our New Drug Application (&#147;NDA&#148;) submission to the U.S. Food and Drug Administration (&#147;FDA&#148;) for CINVANTI&#153; (HTX-019) (&#147;CINVANTI&#148;) and potential regulatory
approval for and commercial launch of CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations or unfavorable warning or cautionary language that the FDA may ultimately impose on the label for CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market opportunities for SUSTOL, CINVANTI and HTX-011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors&#146; activities, including decisions as to the timing of competing product launches, generic entrants, pricing and discounting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical trials and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, potential regulatory approval or further
development of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to meet the post-marketing study requirements within the FDA&#146;s mandated timelines and to obtain favorable results and comply with standard post-marketing requirements including U.S. federal advertising
and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy and security laws, safety surveillance, and disclosure of payments or other transfers of value to healthcare professionals and entities for SUSTOL or any
of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sustained-release
drug delivery technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations and vendor relationships for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints or changes in the regulatory environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third-party infringement claims; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; in this prospectus, as may be
updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and discussed elsewhere in this prospectus and the documents incorporated by reference herein. You should carefully review
all of these factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this prospectus, and except
as required by law, we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may also contain estimates, projections and other information concerning our industry, our business, and the markets for
certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or
circumstances may differ materially from events and circumstances reflected in this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_3"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context requires otherwise, in this Prospectus, the &#147;Company,&#148; &#147;Heron&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; refer to Heron Therapeutics, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on
improving the lives of patients by developing novel best-in-class treatments that address some of the biggest unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from cancer or pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital
Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in February 1983 as a California corporation under the name AMCO Polymerics,
Inc., or AMCO. AMCO changed its name to Advanced Polymer Systems, Inc. in 1984 and was reincorporated in the state of Delaware in 1987. We changed our name to A.P. Pharma, Inc. in May 2001 and changed our name from A.P. Pharma, Inc. to Heron
Therapeutics, Inc. in January 2014. Our executive offices are located at 4242 Campus Point Court, Suite 200, San Diego, California 92121 and our telephone number is (858)&nbsp;251-4400. Additional information regarding our company, including our
audited financial statements and descriptions of our business, is contained in the documents incorporated by reference in this prospectus. See &#147;Where You Can Find Additional Information&#148; on page&nbsp;13 and &#147;Information Incorporated
by Reference&#148; beginning on page&nbsp;13. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before you decide whether to purchase any of our securities, in addition to the
other information, documents or reports included in or incorporated by reference into this prospectus and any accompanying prospectus supplement or other offering materials, you should carefully consider the risk factors in the section entitled
&#147;Risk Factors&#148; in any prospectus supplement to this prospectus as well as in our most recent Annual Report on Form&nbsp;10-K and any subsequent Quarterly Reports on Form&nbsp;10-Q, which are incorporated by reference into this prospectus
and any prospectus supplement in their entirety, as the same may be amended, supplemented or superseded from time to time by our filings under the Exchange Act. For additional information, see the section entitled &#147;Where You Can Find Additional
Information.&#148; These risks could materially and adversely affect our business, results of operations, financial condition and prospects and could result in a partial or complete loss of your investment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds we receive from the sale of securities as set forth in the applicable prospectus supplement. Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling stockholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer preference equity securities under this prospectus, then we will, if required at that time, provide a ratio of combined fixed
charges and preference dividends to earnings in the applicable prospectus supplement for such offering or in a document that we file with the SEC and incorporate by reference in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_7"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Capital Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of our common stock and a summary of our preferred stock. You should refer to our certificate of incorporation
and our bylaws for the actual terms of our capital stock. Copies of our certificate of incorporation and bylaws may be obtained as described under the heading &#147;Where You Can Find Additional Information&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 102,500,000 shares of capital stock of which 100,000,000 shares are of common stock, par value $0.01 per
share, and 2,500,000 shares are of preferred stock, par value $0.01 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that
may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably all dividends, if any, as may be declared form time to time by our Board of Directors out of the funds legally available. In the event
of the liquidation, dissolution or winding up of the Company, the holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then
outstanding. The common stock has no preemptive or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and non-assessable, and the shares of
common stock to be issued upon completion of this offering will be fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;17, 2017,
53,696,906&nbsp;shares of our common stock were issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar. </I>The transfer agent and
registrar for our common stock is Computershare Trust Company&nbsp;N.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing. </I>Our common stock is currently listed on The
NASDAQ Capital Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our certificate of incorporation, our Board of Directors has the authority, without further action by stockholders, to designate up to
2,500,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights,
rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;17, 2017, no shares of preferred stock were issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each
series that we sell under this prospectus and applicable prospectus supplements in the certificate of designations relating to that series. If we issue preferred stock, we will incorporate by reference into the registration statement of which this
prospectus is a part the form of any certificate of designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplement
and any free writing prospectus related to any series of preferred stock we may offer, as well as the complete certificate of designations that contains the terms of the applicable series of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Provisions Affecting Control of Heron Therapeutics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and Bylaw Provisions</I>. Some provisions of Delaware law and our certificate of incorporation and bylaws
contain provisions that could make the following transactions more difficult: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a tender offer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a proxy contest or otherwise; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removal of our incumbent officers and directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are
intended to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock</I>. The ability to authorize undesignated preferred stock makes it possible for our Board of
Directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers
or delaying changes in control or management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Procedures</I>. The advance notice procedures in our
bylaws with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders provide that notice of stockholder proposals must be timely given in
writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first
anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all such stockholder notices. These requirements may have the effect of precluding stockholders from bringing proposals
relating to the nomination of candidates for election as directors or new business before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute</I>. We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware. This law
prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the
affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203
defines &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of our assets involving the interested stockholder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in general, any transaction that results in the issuance or transfer by us of any of our stock to the interested stockholder; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person beneficially owning 15% or more of the
outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
Description of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock or any combination of these
securities. Warrants may be issued independently or together with other securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between a
warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. The following outlines
some of the general terms and provisions of the warrants that we may issue from time to time. Additional terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement. The following description,
and any description of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions of the applicable warrant agreement, which we will file with the
SEC in connection with any offering of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular issue of warrants exercisable for common stock or preferred stock will describe the terms of
the common stock warrants and preferred stock warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price for the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities that the warrants are issued with and the number of warrants issued with each security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares and price of common stock or preferred stock that may be purchased upon exercise of a warrant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants commences and expires; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anti-dilution provisions of the warrants, if any; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption or call provisions, if any, applicable to the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant
will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the number of shares of common stock or preferred stock being offered. Holders may exercise warrants at any time up to the
close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will be void. Holders may exercise warrants as set forth in the prospectus
supplement relating to the warrants being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until a holder exercises the warrants to purchase any securities underlying the
warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<A NAME="toc631920_8"></A>ELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledgees, donees or successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus, any applicable prospectus supplement or post-effective
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding the beneficial ownership of our securities by a selling stockholder, the number of securities being
offered by a selling stockholder and the number of securities beneficially owned by a selling stockholder after the applicable offering, where applicable, will be set forth in a prospectus supplement or in a post-effective amendment. The applicable
prospectus supplement or post-effective amendment will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise has had a material relationship with us during the three years prior
to the date of the applicable prospectus supplement or post-effective amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered by this prospectus from time to time in one or more offerings. Registration of the securities covered by
this prospectus does not mean, however, that those securities will necessarily be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities separately
or together: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through one or more underwriters or dealers in a public offering and sale by them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to investors; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in one or more transactions at a fixed price or prices, which may be changed from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the times of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe the method of distribution of the securities issued
pursuant to this prospectus and the terms of the offering in the applicable prospectus supplement. Discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be
resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters. Generally, the
underwriters&#146; obligations to purchase the securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the securities if they purchase any of the securities. We may use underwriters with whom we
have a material relationship. We will describe in the applicable prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public
offering price set forth in the applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the
applicable prospectus supplement, and the applicable prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the underwriters, dealers and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover
over-allotments, if any, in connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents may receive compensation in the form of
discounts, concessions or commissions from us or our purchasers, as their agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under the Securities Act. As a result, discounts,
commissions or profits on resale received by the underwriters, dealers or agents may be treated as underwriting discounts and commissions. The applicable prospectus supplement will identify any such underwriter, dealer or agent and describe any
compensation received by them from us. Any initial public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, all securities we offer,
other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. Any common stock sold pursuant to a prospectus supplement will be listed for trading on The NASDAQ Capital Market or other principal market for our common stock. We may apply to list any series of preferred stock or warrants on an exchange,
but we are not obligated to do so. Therefore, there may not be liquidity or a trading market for any series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
underwriter may engage in over-allotment transactions, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which
create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market
after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. We make no representation or prediction as to the direction
or magnitude of any effect that such transactions may have on the price of the securities. For a description of these activities, see the information under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148; in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents who may become involved in the sale of the common stock may engage in
transactions with and perform other services for us in the ordinary course of their business for which they receive compensation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<A NAME="toc631920_10">
</A>XPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OUM&nbsp;&amp; Co. LLP, an independent registered public accounting firm, has audited our consolidated financial
statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2016, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our consolidated
financial statements are incorporated by reference in reliance on OUM&nbsp;&amp; Co. LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the issuance of the securities being offered hereby and the binding nature of any warrants being offered hereby is being
passed upon by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_12"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows the Company to &#147;incorporate by reference&#148; the information that is filed by the Company with the SEC, which means that
the Company can disclose important information to you by referring you to those documents. The documents incorporated by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;26, 2017 that have been incorporated by reference into our Annual Report on Form 10-K for the year ended December&nbsp;31,
2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Current Reports on Form 8-K filed with the SEC on January&nbsp;24, 2017,&nbsp;March&nbsp;17, 2017,&nbsp;April&nbsp;3, 2017, April&nbsp;24, 2017, and June&nbsp;13, 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The description of the Company&#146;s common stock contained in the registration statement on Form 8-A, as amended, filed with the SEC on January&nbsp;22, 2014 pursuant to Section&nbsp;12(b) of the Exchange Act,
including any amendment or report filed for the purpose of updating that description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report or documents that is not deemed filed under such provisions, on or after the date of this prospectus until the earlier of the date on which
all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the
date of filing of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded, for purposes of this prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Nothing in this prospectus shall be deemed to
incorporate information furnished, but not filed, with the SEC pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or
oral request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon such person&#146;s written or oral request, a copy of any and all of the information incorporated by
reference in this prospectus, other than exhibits to such documents, unless such exhibits are specifically incorporated by reference into the information that this prospectus incorporates. Requests should be directed to the Secretary at Heron
Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, California 92121, telephone number (858)&nbsp;251-4400. You may also find these documents in the &#147;Investor Relations&#148; section of our website, <I>www.herontx.com</I>. The
information on our website is not incorporated into this prospectus. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, you should not rely on any information that is not
contained in this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc631920_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual,&nbsp;quarterly and special reports,
proxy statements and other information with the SEC. You may read and copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The Company&#146;s filings with the SEC are also available to the public at the SEC&#146;s Internet web
site at <I>http://www.sec.gov</I>. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an
exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>5,063,292 Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g631920g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS&nbsp;SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies
</B></P> <P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June 25, 2018 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g631920g04j69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g631920g04j69.jpg
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ML]/5-#514U1787:!EK*TM=8D)3,W0G%R<['!"3ABAI&AMM%#4E6%I</2_]H
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M9'9>3L"RID4U')O5$&7%BIXJG36;:Q\%WBIM?Q+M:%$+@:3O"V!JQ9J_=*W
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MH.+:EU/7ST.K]4\3>S]GJ,W-U]B+P5Z<HG>=E[DDSA9=U5&2:RPM<58MS<,
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M=G4S682I3B:!<P5>N0D'B$)1!!$+,Q7!P)-)S7R 1*^?AX6_V^'G-_EC#_\
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MWUN)'K[< N)9F(TF6D58CY!\0J50PA\-SV)/L5NL>LA2<\Z\GNJ[1R>'PM?
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M-G?W>U(O0:W[Z.=_&.S/[NZQWM2'FK+VTZ\AT_8\E6RUZ-V>0/=HN-J=D,E
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M"AAB;*I*&(<HHD&J:(&!#,3&H^DV2$V7W9UV[1)(*TQVI-2;%1?9J$):DH2
ME+K)5X2 @"I4-3P*9\I,488J(P_DUH%I9+C24-N>K$SNULUU+Q$XIR[R=OX#
M,1E;-4Q=6JOR3JBZM1EA<DKTLXKL9->#EHK&3(8B)XAYW:N<ZGX8L2]=].W=
MOYF,M9JF+ZM1^3=454J,L+DE>EG"&,FO!2T5#)D,1!<=YWC_  .UW^.S2/\
MQ'@N>GJ?\G:G\9=L_P!L5=>KJI\FZ?\ &?;']LU=2?NW[#+=^+$__=1?)OD_
MUMR'VC;_ *NS4[R?ZVY#[1M_U=FJLZN/(5K1WCRW<;&R,SKK3PTH3L<2,")E
M'H2,N=4*KL7?B8P1M\HF.HY^5'R#P@Y!8(Y2BFF<MMOK;HVD#:6V.D6YF)=9
MP^W5O/,K2HWE61DJ!TT94T+$C-.,;RUI+ V* Y8(]HG,4-1!U+:W1[=#4NLX
M;;@//-+0HWE51DZ!TT9<T+$F&G%NY:XE@;% R6"/;!R-G\+L?7UCAVK! 7FH
MS,&\RDAN7C+'$&1V65)]?U\EL%K81C"?G7A:TJ1G&<+PG.,XQ=U;,8BY7&W4
MRF/LU2'O&PFY78F1XYY\0&2,>7Q\S''V>)U>E;-8>[6&Y4RN.LU3&#&PB[78
MF1F.>?$%DC'E\?,Q,?9XG6!L[IK%ZN>PV:%K,7;E<H.L9[%AV/ NQAPTY8%N
M+(SI&HDOQCHEKD)0-A9DRD*P8A(LQT&.DV\R!6$-17Z):64R67'%85>X*>*P
M=OTO,5"2T+5N2D_H9QYD@EWVO6,LLPNWZ,ADJ2\9:<1$3G<U'*Y+,CB<&O<5
M/$8*WZ9FJA(:%JY,R?T+XXR02K[K"AEEF%W(JUV$I+QEQ\#C'3U)U-9*5$3W
M7_L)L_5<"2(DQ.NXJ]U2R1=$D"?2_)5L^F[-@;NY6R8N0<)'.AAW0!FB4NK&
M3D=QIQ>#V[C,!=QM>WM+=V<P51BX9&'1E*%U&+<?KNILQV;J9,J;$.DQ;7 E
M!!P1!'84%.#VYB]O7<97M[0WAG<!48N&^\]?*X^ZC%./UWTFXW.4\H5)B'28
MMK"2@$X*0CL*)GTNL-J;!'[#F:2.V'6M[U9K7Y5OD[Q#0,5"V'7LNS+,QP%;
MN3]5)<J!CLZSETJ.''CH.9QZBR' ,@,X>>]V#SN7'=[-LMR]+=-$<2S(/R=:
MHBM;Q%@; I53R)T#+'L*T/)I 4U;/JR<J\(>X_;@L_F WBS:[<S2W70'$,R3
M\I6J5ZMS#V1L"E5+)%CV%CF%:"2-("BK9\I.52H>XIK<LK5G:<::<::<::<:
M:<::<::PSV)_ 7M?\1Y[^Q.<C>\/DMG_ +EV_P E.HSO/Y*;@^Y=K\G.L@4K
M]AM2_%F!_NH7F7QOZW4/M*K^07K,8S];<?\ :-3^KKUAOJ]^#(O^,+9?^^TS
MR-[&_6-GW7S7]IV=1K8GZQM^[.<_M.SKF=I?VOVT/Q?1_>8'.W?7R2SOVG_^
MY6NW?GR0SOVG'Y=6H'>0+]D.J?Q,,_MP_*JZN?JS _<YOY4-5-U>_5FW_N8S
M\J&J]N5!JGM7+ZO_ &9]4OY-1_\ =].YLC@_URV#_$IOY'&ZV7P7ZY=/_P")
M#?R.+U.'EGZM'5:/6+\,=<_$/</_ !B?Y2NQ_E%3^Y.X_P#U(6J1V/\ *6E]
MR=R?^I6:LNY=6KNU6?N;_P"/]S/_ )8?[\KW*5W'^JNH_P#W*_K-/5([E_5O
M4K_N'_6J6K,.75J[M8,[,?@$VG^*AG]8SR+[U^2F>^Y[?^(ZBN^/DEG_ +GM
M_P"(ZU^N:CZU!U9GXX_^F;=_T:C?UMLY=O1K_*;A_P!C%_TLAJ\>B_\ E-Q_
M[&*_I9'56'D%_;&VS_7C_P#79Y1O5OY87_MEO]/5#=7OEI>^VF_E=7?] _VN
M=<_T\W^I$YLWTG^1]3_?-_HKUM%TC^1E/_?-_H*UDKL_^#J(_C+UE_OC%\S.
M^/UGK?=O"?VDC6<WS^LU;[N8+^TZ^LX67]CE@_U)*_V!_DHN?J.W]K/_ "1:
ME%[]17/M6Q^2/6*NMOX!=6?B?'?^CG,!LKY*8'[GJ_XEK ;)^2> ^YR?^>M:
M#L=^V.E?QC(_M:^:7;R^65C[=G\IK2'>GRRL_;Y_E(ULZZ(_ [KO\60?_1?-
MVMK?)W$?:2O^>MYMI_)S#_:2_P#B6M>SR5?M@9W_ $M/]4US4;K-\K[?^\#^
MCK3[K9\L;?\ O!_H1JW/QR?M>P_]</\ ]E%YL#T<^2*_MD_R:];#=%_D@O[8
9G\F&I]<M?5N:<::<::<::<::<::<::__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
